Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep322 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Switching from liraglutide to dulaglutide, is it worth it?: Outcomes at 24 weeks follow-up

Cayón-Blanco Manuel , García-Figueras-Mateos Carolina

Introduction: Once-daily liraglutide and once-weekly dulaglutide, both glucagón-like peptide-1 receptor agonists, improve glycemic control and reduce weight in patients with type 2 diabetes mellitus (T2DM) with a similar efficacy according to head-to-head trial AWARD-6. Nevertheless, there is a lack of evidence in a real-world setting. The focus of our study is to assess changes in glycemic control and weight resulting from switching from liraglutide to dulaglutide in pat...

ea0070aep487 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to a glucagon-like peptide-1 receptor agonist: A real-world experience

García-Figueras-Mateos Carolina , Cayón-Blanco Manuel

Introduction: Glucagon-like peptide-1 agonists (GLP1a) and dipeptidyl peptidase-4 inhibitors (DPP4i) are both incretin-based therapies for type 2 diabetes (T2DM) but with distinct efficacy according to glycemic and weight control and side effect profiles. There is scarce information about changes observed after switching from a DPP4i to a GLP1a in patients with T2DM on a complex treatment regimen and routine clinical practice conditions. To assess these changes, we carried out...

ea0070aep869 | Thyroid | ECE2020

Tocilizumab for corticoid-resistant Graves’ orbitopathy: A case report

Cayón-Blanco Manuel , García-Figueras-Mateos Carolina , Carlos Anglada-Pintado Juan

Introduction: Graves’ ophthalmopathy (GO) is an autoimmune disorder that constitutes a major clinical and therapeutic challenge. Current treatment options for moderate-to-severe GO include immunotherapy, orbital radiotherapy and decompression surgery. Limited drugs of proven efficacy are available for the treatment of people with GO. Given the role in the pathogenesis of GO of interleukin (IL)-6 expression in adipocytes, fibroblasts and macrophages, the proposed theory i...

ea0049ep619 | Diabetes therapy | ECE2017

Incretin-based therapies and pancreatic/biliary tract cancer

Boj-Carceller Diana , Cay-Melero Sara , Azcona-Monreal Isabel , Perez-Fernandez Leticia , Calmarza-Calmarza Pilar , Sanz-Paris Alejandro

Objective: To study the relation between incretin-based therapies, DPP-4 inhibitors and GLP-1 receptor agonists, and tumor stage at the time of diagnosis of pancreatic and biliary tract cancer.Methods: Retrospective study of type 2 diabetic patients with newly diagnosed of pancreatic or biliary tract cancer attended consecutively in a tertiary hospital between the years 2012 and 2015.Results: A total of 37 patients were included. T...

ea0084op-08-37 | Oral Session 8: Basic 2 | ETA2022

Resistance to thyroid hormone alpha: molecular, biochemical and physiological approach to diagnosis and therapy

Agostini Maura , Pietzner Maik , Marelli Federica , Prapa Matina , Moran Carla , Edward Visser W. , Brown Dave , Thomas Ellen , Schoenmakers Erik , Romartinez-Alonso Beatriz , Scheuplein Rabea , Tylki-Szymanska Anna , Lyons Greta , Watson Laura , Rajanayagam Odelia , Schwedhelm Edzard , F. Hartmann Michaela , Wudy Stefan , Probst Maiken , MacDonald Stephen , Thomas William , Arlt Wiebke , Volker Uwe , M. Main Katharina , Feldt-Rasmussen Ulla , T. Dattani Mehul , Koren Dahll Louise , Demir Korcan , Kara Cengiz , Kirbiyik Ozgur , Mammadova Jamala , Cayır Atilla , Yarali Oguzhan , Phan-Hug Franziska , Sakremath Rajesh , Mohamed Zainaba , Shinawi Marwan , Gill Harpreet , pacaud Daniele , Perrier Renee , Poke Gemma , Hunter Wendy , Douzgou Sofia , Wakeling Emma , Gardham Alice , Lim Derek , Shears Deborah , Freel Marie , Omladic Jasna , Tansek Mojca , Writzl Karin , Farooqi Sadaf , Kopp Peter , Schwabe John , Persani Luca , Chatterjee Krishna

Objectives: THRA mutations cause Resistance to Thyroid Hormone α (RTHα), an underdiagnosed disorder with hypothyroid features but near-normal thyroid function tests (TFTs). We developed a pathway, combining molecular analyses, new biomarkers and physiological measurements, to better diagnose and treat this disorder.Methods: Structural and functional analyses of THRA variants, discovered by next generation sequencing in specifi...